Avivit Ochaion

1.5k total citations
19 papers, 1.2k citations indexed

About

Avivit Ochaion is a scholar working on Physiology, Oncology and Cancer Research. According to data from OpenAlex, Avivit Ochaion has authored 19 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Physiology, 8 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Avivit Ochaion's work include Adenosine and Purinergic Signaling (15 papers), Peptidase Inhibition and Analysis (7 papers) and NF-κB Signaling Pathways (7 papers). Avivit Ochaion is often cited by papers focused on Adenosine and Purinergic Signaling (15 papers), Peptidase Inhibition and Analysis (7 papers) and NF-κB Signaling Pathways (7 papers). Avivit Ochaion collaborates with scholars based in Israel and United States. Avivit Ochaion's co-authors include Pnina Fishman, Sara Bar‐Yehuda, Lea Madi, Faina Barer, Lea Rath‐Wolfson, Shira Cohen, S. Bar‐Yehuda, R. Patoka, Gil Ohana and Ehud Baharav and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Avivit Ochaion

17 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Avivit Ochaion Israel 15 866 490 240 187 137 19 1.2k
Faina Barer Israel 18 1.0k 1.2× 578 1.2× 300 1.3× 202 1.1× 192 1.4× 26 1.4k
Sara Bar‐Yehuda Israel 24 1.5k 1.7× 872 1.8× 395 1.6× 299 1.6× 267 1.9× 33 2.0k
Xiaofeng Sun China 20 555 0.6× 579 1.2× 217 0.9× 347 1.9× 16 0.1× 32 1.3k
Diane Bouïs United States 11 185 0.2× 357 0.7× 92 0.4× 139 0.7× 23 0.2× 15 909
Letícia Scussel Bergamin Brazil 15 252 0.3× 205 0.4× 77 0.3× 145 0.8× 13 0.1× 24 643
Gilles Alberici France 15 226 0.3× 216 0.4× 305 1.3× 367 2.0× 22 0.2× 33 1.0k
Mouer Wang United States 21 50 0.1× 719 1.5× 154 0.6× 272 1.5× 59 0.4× 33 1.4k
Yohta Shimada Japan 19 66 0.1× 365 0.7× 70 0.3× 45 0.2× 93 0.7× 51 875
Caroline Sevin France 20 65 0.1× 551 1.1× 61 0.3× 45 0.2× 23 0.2× 54 1.4k
Kazuki Sawamoto Japan 19 32 0.0× 417 0.9× 141 0.6× 105 0.6× 121 0.9× 39 1.4k

Countries citing papers authored by Avivit Ochaion

Since Specialization
Citations

This map shows the geographic impact of Avivit Ochaion's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Avivit Ochaion with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Avivit Ochaion more than expected).

Fields of papers citing papers by Avivit Ochaion

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Avivit Ochaion. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Avivit Ochaion. The network helps show where Avivit Ochaion may publish in the future.

Co-authorship network of co-authors of Avivit Ochaion

This figure shows the co-authorship network connecting the top 25 collaborators of Avivit Ochaion. A scholar is included among the top collaborators of Avivit Ochaion based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Avivit Ochaion. Avivit Ochaion is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Cohen, Shira, Salomon M. Stemmer, Avivit Ochaion, et al.. (2010). CF102 an A3 adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liver. Journal of Cellular Physiology. 226(9). 2438–2447. 73 indexed citations
2.
Ochaion, Avivit, S. Bar‐Yehuda, Shira Cohen, et al.. (2009). The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease. Cellular Immunology. 258(2). 115–122. 104 indexed citations
3.
Bar‐Yehuda, S., Lea Rath‐Wolfson, Luis Del Valle, et al.. (2009). Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. Arthritis & Rheumatism. 60(10). 3061–3071. 107 indexed citations
4.
Stemmer, Salomon M., Lea Madi, David Castel, et al.. (2008). CF102 an A3 adenosine receptor agonist induces in vivo apoptosis of Hepatocellular carcinoma. Cancer Research. 68. 5712–5712.
5.
Ochaion, Avivit, S. Bar‐Yehuda, Shira Cohen, et al.. (2008). The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochemical Pharmacology. 76(4). 482–494. 60 indexed citations
6.
Stemmer, Salomon M., Lea Madi, David Castel, et al.. (2008). Effect of CF102 on growth suppression and apoptosis in an orthotopic model of hepatocellular carcinoma. Journal of Clinical Oncology. 26(15_suppl). 22113–22113. 1 indexed citations
7.
Fishman, Pnina, Kenneth A. Jacobson, Avivit Ochaion, Shira Cohen, & S. Bar‐Yehuda. (2007). The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel, Targeted Therapy. Immunology Endocrine & Metabolic Agents - Medicinal Chemistry. 7(4). 298–303. 19 indexed citations
8.
Bar‐Yehuda, Sara, Michael H. Silverman, William Kerns, et al.. (2007). The anti-inflammatory effect of A3adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opinion on Investigational Drugs. 16(10). 1601–1613. 77 indexed citations
9.
Fishman, Pnina, et al.. (2007). Over-expression of the A3 adenosine receptor in tumor and PBMC of hepatocellular carcinoma patients: A specific therapeutic target. Journal of Clinical Oncology. 25(18_suppl). 14085–14085.
10.
Fishman, Pnina, Sara Bar‐Yehuda, Lea Madi, et al.. (2006). The PI3K–NF-κB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Research & Therapy. 8(1). R33–R33. 79 indexed citations
11.
Ochaion, Avivit, Sara Bar‐Yehuda, Luis Del Valle, et al.. (2006). Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3adenosine receptor expression. Arthritis Research & Therapy. 8(6). R169–R169. 51 indexed citations
12.
Rath‐Wolfson, Lea, S. Bar‐Yehuda, Lea Madi, et al.. (2006). IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis.. PubMed. 24(4). 400–6. 53 indexed citations
13.
Baharav, Ehud, Sara Bar‐Yehuda, Lea Madi, et al.. (2005). Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models.. PubMed. 32(3). 469–76. 80 indexed citations
14.
Liang, Xue‐hai, Avivit Ochaion, Yuxin Xu, Qing Liu, & Shulamit Michaeli. (2004). Small Nucleolar RNA Clusters in Trypanosomatid Leptomonas collosoma. Journal of Biological Chemistry. 279(7). 5100–5109. 14 indexed citations
15.
Madi, Lea, Avivit Ochaion, Lea Rath‐Wolfson, et al.. (2004). The A3 Adenosine Receptor Is Highly Expressed in Tumor versus Normal Cells. Clinical Cancer Research. 10(13). 4472–4479. 164 indexed citations
16.
Madi, Lea, et al.. (2003). A3 Adenosine Receptor Activation in Melanoma Cells. Journal of Biological Chemistry. 278(43). 42121–42130. 80 indexed citations
17.
Fishman, Pnina, Sara Bar‐Yehuda, Gil Ohana, et al.. (2003). An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3β and NF-κB. Oncogene. 23(14). 2465–2471. 85 indexed citations
18.
Fishman, Pnina, et al.. (2003). Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist.. PubMed. 23(3A). 2077–83. 82 indexed citations
19.
Bar‐Yehuda, Sara, et al.. (2002). Agonists to the A3 adenosine receptor induce G-CSF production via NF-κB activation. Experimental Hematology. 30(12). 1390–1398. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Faina Barer Breakdown of academic impact, for papers by Sara Bar‐Yehuda Breakdown of academic impact, for papers by Xiaofeng Sun Breakdown of academic impact, for papers by Diane Bouïs Breakdown of academic impact, for papers by Letícia Scussel Bergamin Breakdown of academic impact, for papers by Gilles Alberici Breakdown of academic impact, for papers by Mouer Wang Breakdown of academic impact, for papers by Yohta Shimada Breakdown of academic impact, for papers by Caroline Sevin Breakdown of academic impact, for papers by Kazuki Sawamoto
Rankless by CCL
2026